Figure 4.

Anti-cancer therapy strategies based on targeting of FGF/FGFR. Ligand traps are fusion molecules that prevent FGF binding and subsequent receptor dimerization. Monoclonal antibodies neutralize specific members of the FGF family members. Chemical receptor tyrosine kinase inhibitors (TKi) are able to inhibit FGFR activation and phosphorylation. Finally, microRNA molecules are capable of silencing both oncogenes and tumor suppressors. Targeting the FGF/FGFR axis with these agents may hold promise for anti-cancer treatment, including overcoming chemoresistance.